Decoy Therapeutics engineers next-generation peptide conjugate therapeutics using its proprietary IMP 3 ACT™ platform. This computational approach rapidly designs drug candidates, optimizing for affinity, pharmacokinetics, and scalable manufacturing. The company focuses on developing broad-acting antivirals for respiratory viruses and targeted peptide-drug conjugates for colorectal cancers.
Funding
$7.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MLFounders
Product
Problem
Current antiviral treatments are often strain-specific, rendering them ineffective against emerging viral mutations and novel viral threats. This limitation necessitates the development of broad-spectrum antivirals that can target a wide range of viruses, providing preemptive protection against future outbreaks.
Solution
Decoy Therapeutics engineers peptide conjugate therapeutics designed to act as broad-spectrum antivirals. Their approach aims to overcome the limitations of existing antiviral treatments by creating a more versatile and proactive defense against both current and emerging viral strains. These therapeutics are designed to target conserved viral mechanisms, thereby inhibiting viral entry and replication across a wide range of viral species. By focusing on fundamental viral processes, Decoy Therapeutics seeks to provide a preemptive shield against future viral threats, reducing the reliance on reactive, strain-specific treatments.
Target Audience
The primary target audience includes pharmaceutical companies, government agencies, and healthcare providers seeking advanced antiviral solutions for both therapeutic and prophylactic applications.
Features
- Peptide conjugate design targeting conserved viral mechanisms
- Broad-spectrum antiviral activity against current and emerging viral strains
- Inhibition of viral entry and replication
- Preemptive protection against future viral threats